The presence of circulating tumor cells in the blood appears to have no relationship to survival in women who have just been diagnosed with inflammatory breast cancer, according to new research from Fox Chase Cancer Center. ...
Dec 9, 2011
0
0
Triple-negative breast cancer is a particularly aggressive form of breast cancer. Here, important receptors are missing, which often serve as targets for treatments. Thus, these tumors are unlikely to respond to current therapies. ...
Aug 6, 2018
0
30
When a breast cancer tumor is removed with no signs of cancer left behind, it's great news for patients, and now scientists have more evidence of why.
Apr 1, 2019
0
97
Two studies from Washington University School of Medicine in St. Louis focused on breast cancer and pancreatic cancer suggest that specific types of senescent cells—cells that have stopped dividing and drive inflammation—may ...
Jul 19, 2024
0
2
The microenvironment surrounding tumors in HER2+ breast cancer protects them and helps them develop resistance to the most widely used treatment, the monoclonal antibody trastuzumab. And a particular type of cell in this ...
Oct 14, 2022
0
63
New research from the University of Michigan Comprehensive Cancer Center finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative – and that the drug Herceptin, ...
Feb 26, 2013
0
0
T-cells play an important role in the body's immune system, and one of their tasks is to find and destroy infection. However, T-cells struggle to identify solid, cancerous tumors in the body. A current cancer therapy is using ...
Aug 17, 2018
0
18
Breast cancer and type 2 diabetes would seem to be distinctly different diseases, with commonality only in their commonality. Breast cancer is the second most diagnosed malignancy after some types of skin cancer; approximately ...
May 30, 2022
0
50
In a first-in-human, Phase I trial, researchers at The University of Texas MD Anderson Cancer Center discovered that ATR inhibitor RP-3500 was safe and well tolerated with promising clinical benefit. Principal investigator ...
Oct 8, 2021
0
29
Tacrolimus, a drug that is commonly used to prevent organ transplantation rejection, inhibits breast cancer growth in pre-clinical studies. The finding from UNC scientists was reported in the May 26th PLoS ONE.
May 26, 2011
0
0
